Bio-Rad Laboratories Long Term Debt 2010-2022 | BIO.B

Bio-Rad Laboratories long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • Bio-Rad Laboratories long term debt for the quarter ending June 30, 2022 was $1.197B, a 11004.4% increase year-over-year.
  • Bio-Rad Laboratories long term debt for 2021 was $0.011B, a 14.23% decline from 2020.
  • Bio-Rad Laboratories long term debt for 2020 was $0.012B, a 9.73% decline from 2019.
  • Bio-Rad Laboratories long term debt for 2019 was $0.014B, a 96.91% decline from 2018.
Bio-Rad Laboratories Annual Long Term Debt
(Millions of US $)
2021 $11
2020 $12
2019 $14
2018 $439
2017 $435
2016 $434
2015 $434
2014 $436
2013 $436
2012 $732
2011 $732
2010 $731
2009 $738
Bio-Rad Laboratories Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $1,197
2022-03-31 $1,197
2021-12-31 $11
2021-09-30 $11
2021-06-30 $11
2021-03-31 $11
2020-12-31 $12
2020-09-30 $12
2020-06-30 $12
2020-03-31 $12
2019-12-31 $14
2019-09-30 $438
2019-06-30 $438
2019-03-31 $438
2018-12-31 $439
2018-09-30 $439
2018-06-30 $439
2018-03-31 $435
2017-12-31 $435
2017-09-30 $434
2017-06-30 $434
2017-03-31 $434
2016-12-31 $434
2016-09-30 $434
2016-06-30 $434
2016-03-31 $434
2015-12-31 $434
2015-09-30 $436
2015-06-30 $436
2015-03-31 $436
2014-12-31 $436
2014-09-30 $436
2014-06-30 $436
2014-03-31 $436
2013-12-31 $436
2013-09-30 $436
2013-06-30 $733
2013-03-31 $733
2012-12-31 $732
2012-09-30 $732
2012-06-30 $732
2012-03-31 $732
2011-12-31 $732
2011-09-30 $732
2011-06-30 $731
2011-03-31 $731
2010-12-31 $731
2010-09-30 $734
2010-06-30 $734
2010-03-31 $739
2009-12-31 $738
2009-09-30 $739
2009-06-30 $738
2009-03-31 $444
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $15.412B $2.923B
BIO-RAD LABORATORIES, INC. manufactures and supplies to life sciences research, healthcare, analytical chemistry, semiconductor and other markets a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00